Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics, Inc. (CYCN)
Company Research
Source: Business Wire
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseasesKorsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s diseaseConcurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027Conference call scheduled for April 1, 2026, at 8:00 am ET WALTHAM, Mass.--(BUSINESS WIRE)--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Korsana Bio
Show less
Read more
Impact Snapshot
Event Time:
CYCN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYCN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYCN alerts
High impacting Cyclerion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CYCN
News
- Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?PR Newswire
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF)GlobeNewswire
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF)GlobeNewswire
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)PR Newswire
- CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersBusiness Wire
CYCN
Sec Filings
- 4/1/26 - Form 425
- 4/1/26 - Form 8-K
- 3/31/26 - Form 10-K
- CYCN's page on the SEC website